Nanobac Pharmaceuticals Incorporated (NNBP)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 12-2003 | 12-2002 | 12-1999 | 12-1998 | 12-1997 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 50 | 0 | 0 | N/A | 0 |
| Receivables | 6 | 5 | 0 | 1,950 | 2,050 |
| Inventories | 10 | 0 | 0 | N/A | N/A |
| Other current assets | 14 | 0 | 2,080 | 70 | 150 |
| TOTAL | $80 | $5 | $2,080 | $2,020 | $2,200 |
| Non-Current Assets | |||||
| PPE Net | 130 | 0 | 3,070 | N/A | N/A |
| Other Non-Current Assets | 8,020 | 0 | 350 | 920 | 1,160 |
| TOTAL | $8,150 | $N/A | $3,420 | $920 | $1,160 |
| Total Assets | $8,240 | $5 | $5,510 | $6,650 | $8,100 |
| Liabilities | |||||
| Current Liabilities | |||||
| Short Term Debt | 0 | 0 | 190 | 680 | 410 |
| Accounts payable and accrued liabilities | 750 | 260 | 2,180 | 1,860 | 1,650 |
| Accrued Expenses | 360 | 80 | 2,190 | 1,260 | 1,130 |
| Other current liabilities | 0 | 0 | 120 | N/A | N/A |
| TOTAL | $6,850 | $340 | $10,690 | $7,460 | $8,390 |
| Non-Current Liabilities | |||||
| Long Term Debt | 0 | 0 | 0 | N/A | 590 |
| TOTAL | $2,200 | $N/A | $N/A | $2,130 | $590 |
| Total Liabilities | $9,050 | $340 | $10,690 | $9,710 | $9,160 |
| Shareholders' Equity | |||||
| Common Shares | 4,230 | 1,130 | 0 | 2 | 0 |
| Retained earnings | -5,170 | -1,470 | -9,370 | -7,960 | -3,950 |
| Other shareholders' equity | 140 | 0 | 570 | 1,478 | 10 |
| TOTAL | $-800 | $-340 | $-5,180 | $-3,060 | $-1,050 |
| Total Liabilities And Equity | $8,250 | $0 | $5,510 | $6,650 | $8,110 |